Rezolute, Inc. 公布了其针对肿瘤性高胰岛素血症的候选药物Ersodetug，在关键性三期临床试验“Uplift”中取得积极中期数据。
这项研究旨在评估Ersodetug治疗这一罕见且严重疾病的有效性与安全性。中期数据显示，该药物在主要疗效终点上表现出积极趋势，达到了预设的统计显著性标准，显示出良好的治疗潜力。
公司表示，这些数据增强了他们对Ersodetug成功完成三期临床研究的信心。肿瘤性高胰岛素血症是一种由胰腺肿瘤导致胰岛素过度分泌的疾病，可能引发危及生命的严重低血糖。目前，该疾病的有效治疗方案非常有限。
此次积极的中期分析结果，标志着Rezolute在该药物开发道路上迈出了重要一步。公司计划继续推进Uplift研究的完整数据收集与分析，并期待在未来与监管机构进行沟通。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.